This HTML5 document contains 253 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n8http://dx.doi.org/10.1016/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q30315977
rdf:type
wikibase:Item
schema:description
2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած articolo scientifico artikull shkencor scienca artikolo vědecký článek artigo científico (publicado na 2015) επιστημονικό άρθρο vitskapeleg artikkel 2015年论文 2015年論文 სამეცნიერო სტატია 2015年論文 mokslinis straipsnis teaduslik artikkel vetenskaplig artikel article científic 2015年论文 2015年の論文 artigo científico wetenschappelijk artikel 2015年論文 научная статья مقالة علمية (نشرت في 5-11-2015) artykuł naukowy 2015년 논문 bài báo khoa học научни чланак tudományos cikk artigo científico (publicado na 2015) wissenschaftlicher Artikel 2015 nî lūn-bûn научни чланак 2015年论文 videnskabelig artikel (udgivet 2015) artikulong pang-agham naučni članak vedecký článok 2015年论文 artículu científicu espublizáu en 2015 سائنسی مضمون мақолаи илмӣ bilimsel makale scientific article ২০১৫-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ מאמר מדעי 2015年论文 artículo científico publicado en 2015 2015年論文 мақолаи илмӣ article scientific tieteellinen artikkeli научна статия 2015年論文 2015 թվականի նոյեմբերին հրատարակված գիտական հոդված مقالهٔ علمی บทความทางวิทยาศาสตร์ articol științific 2015年论文 наукова стаття, опублікована в листопаді 2015 article scientifique (publié 2015) vitenskapelig artikkel
p:P577
wds:Q30315977-E300FC54-B05F-4B21-9348-56A5B4C7CBDA
wdt:P577
2015-11-05T00:00:00Z
p:P2860
wds:Q30315977-49694BFF-B892-4F64-9B82-5807B6E22B0F wds:Q30315977-49DF8F10-77E9-437E-A3DA-F300394A42A6 wds:Q30315977-5AE57493-AF76-491F-A28E-090004378D3F wds:Q30315977-5B684342-44F0-4A98-8333-F1EDC6434A04 wds:Q30315977-80DDA058-832A-47A0-8D62-0559883EC173 wds:Q30315977-8CFC7373-C592-4A86-B122-4E564BA33F54 wds:Q30315977-70CDF6F6-4503-4EA5-8BD8-0542F161C713 wds:Q30315977-78B00CEA-AE71-44FC-AD67-4DE57920209A wds:Q30315977-7FB76D19-E2CF-40B8-8C57-1F80548657FE wds:Q30315977-CC542275-9817-4A5F-838B-6334E9F837B7 wds:Q30315977-D5A0D8AB-E604-4595-864C-AA05BB783EC6 wds:Q30315977-B8F8A0DF-652A-44F6-89A6-892D3A337B9C wds:Q30315977-BB865056-82C6-45FB-9980-CEFCE77E14F3 wds:Q30315977-0254AA53-0DDA-4D64-8A5B-E2A916A73B22 wds:Q30315977-03B97A84-EE37-4CD4-8145-1B827D4B66B2 wds:Q30315977-0512E4A2-2B5F-4C06-9F4F-5AAF5F2DD919 wds:Q30315977-07758B8F-083A-4251-A41F-1BE45B6F820A wds:Q30315977-DAE0F7D2-26B7-4CF0-BF29-AADA7DD4116E wds:Q30315977-E15BC4DA-D99E-493A-8BDA-C8D2A01D1A80 wds:Q30315977-FCE0043F-E91E-4C58-95E2-42CF26945401 wds:Q30315977-F1FC8FF3-9BD6-4DF4-B048-3CC9F0783D4B wds:Q30315977-16490FFE-16CD-4628-A264-B6BA9F2F26A2 wds:Q30315977-20B10AFC-6CDD-4581-922E-FEDB2F27701D wds:Q30315977-147F79BE-1E62-41C1-BBA1-07CD42E42F83 wds:Q30315977-38215481-569F-418C-8DB4-2AE42C892EB2 wds:Q30315977-2538AD03-40C2-4819-B48C-E9A79D10B8C7 wds:Q30315977-3ED651E6-9AFE-434D-917C-F8D013B157A2 wds:Q30315977-406DFF17-F35D-410C-82F2-DE0134F6FE23 wds:Q30315977-42F49025-EA71-446D-8268-1D4AAF637D12 wds:Q30315977-3C2706D3-E041-426E-8375-CED6DFB194B5
wdt:P2860
wd:Q27851459 wd:Q47903403 wd:Q27851423 wd:Q36610990 wd:Q34095013 wd:Q82350053 wd:Q27851430 wd:Q40024347 wd:Q34282342 wd:Q34630212 wd:Q34451540 wd:Q84138224 wd:Q33772438 wd:Q54517330 wd:Q27851417 wd:Q42971619 wd:Q34565246 wd:Q43086258 wd:Q33880828 wd:Q84244801 wd:Q22299206 wd:Q44189526 wd:Q39924433 wd:Q34523534 wd:Q34448978 wd:Q46931556 wd:Q43074202 wd:Q36907832 wd:Q28242368 wd:Q38447207
p:P2093
wds:Q30315977-B3C498F0-14FE-4607-86FB-033EA9BF696E wds:Q30315977-BC5DE17C-01EF-45AA-B813-A70AF69D93DA wds:Q30315977-676E4E84-C8A9-4A77-B99C-8FB1147902DB wds:Q30315977-76ECFDB6-08F4-4F41-81D5-76C14BA1CE9C wds:Q30315977-80CD1085-79E7-4D96-9F28-D30042EF5C2A wds:Q30315977-43E350FD-1957-4150-B480-5821288EC735 wds:Q30315977-561F0322-E2DC-4D77-BE7E-4DFF0464D1BC wds:Q30315977-15035446-2C1C-4A21-B8BF-1EA0AD990599 wds:Q30315977-146E46C9-9D94-4146-BE64-681E7F120F50 wds:Q30315977-2C1A3442-F38A-439A-B6D5-6DAE708D6A66 wds:Q30315977-03D34922-4440-475F-8C81-C2B6AF1A6D8C wds:Q30315977-13D3A563-0BBA-46F3-B4D3-C91810F8ED79 wds:Q30315977-0D9FA92B-B39F-42C3-A337-738EC4BD6C2F wds:Q30315977-D6582E9D-1917-4378-A07B-8EB2E5BED982 wds:Q30315977-EFA1C213-0541-494B-AE38-9B51D21121DA wds:Q30315977-FF1F78D6-D066-425C-822E-0466C72B251E
wdt:P2093
Thomas Geer Hartmut Link Andreas Neubauer Wolfgang E Berdel Albert Reichle Michael Kramer Heinz Dürk Andreas Mackensen Andreas Hüttmann Stefan W Krause Christian Junghanß Study Alliance Leukaemia Regina Herbst Martin Görner Jana Hase Ulrich Kaiser
rdfs:label
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
skos:prefLabel
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
schema:name
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
p:P50
wds:Q30315977-3B8FDEBD-1940-4210-89E5-4F9DF5C972D6 wds:Q30315977-40B5DE29-B156-43AF-A1F3-F1CEFFBE2D11 wds:Q30315977-23DBE034-23B2-40B8-8E4A-81C7C797DF81 wds:Q30315977-2517BA95-92FC-410C-AC30-27A0AACAA195 wds:Q30315977-3401A107-17E8-4638-B95F-84ACA098EBA0 wds:Q30315977-151C706C-3BD5-4982-8CA3-5834C8B2D06A wds:Q30315977-B2A006EB-3200-487D-B011-C304778F02CA wds:Q30315977-C6BAE90B-406E-465A-927F-8659014B0752 wds:Q30315977-9329ECA9-2F5E-4F60-BDA7-44DFA2D740BF wds:Q30315977-9B624BEF-BD7F-4FD7-8003-E5D988AEA47C wds:Q30315977-9EFF0D40-B4C8-47C0-A81F-80DD7FED690A wds:Q30315977-A3018F05-F240-4B44-80D8-C4B6FDE8E155 wds:Q30315977-A88031D4-614B-4709-9304-918D3C296E33 wds:Q30315977-ADEAECE5-2473-475C-9D14-6B06E7F93492 wds:Q30315977-65FBE564-98AD-443A-AD94-E40B12C779CF wds:Q30315977-68CF74C6-D328-425C-A1B7-3DF70D75996C wds:Q30315977-704BE9BB-9E81-484C-A9D0-6D5624599443 wds:Q30315977-F54D40D8-7BA4-4C92-A479-610FABD260D7 wds:Q30315977-F86A5663-87B2-4019-A8F0-A0867F67F612 wds:Q30315977-FAA0DE9C-CA37-47EB-B8D4-630555403CD1 wds:Q30315977-E2A54C47-90A5-492A-833F-5EFC807C7E77 wds:Q30315977-E50CC40E-B619-49EE-91C0-41C1F3563120 wds:Q30315977-072EE37B-EC5D-4BF9-9707-0E3560F498A5 wds:Q30315977-08E9E996-5257-4B37-8E17-2EE3411F790E wds:Q30315977-0DD053B8-74A6-46CF-86D3-7165BE2F9914 wds:Q30315977-10319984-0AC3-4894-B941-9CAE5D1D5689 wds:Q30315977-4B371530-CBC0-4FD5-B2A8-B3D946545E3D wds:Q30315977-4F031FC2-2A2F-4597-8F99-01238BB0D354 wds:Q30315977-580EDFDC-2861-4DF3-BE04-DE7900096808 wds:Q30315977-3A410056-BA17-4609-8EE9-BCB1CA162DED
wdt:P50
wd:Q71785823 wd:Q117235548 wd:Q117235584 wd:Q117235576 wd:Q1610986 wd:Q117235578 wd:Q39186141 wd:Q86941191 wd:Q59691122 wd:Q114293352 wd:Q87777753 wd:Q117235577 wd:Q117235585 wd:Q117235582 wd:Q117235583 wd:Q114529739 wd:Q114516541 wd:Q117235541 wd:Q117235546 wd:Q117223791 wd:Q42323747 wd:Q92308646 wd:Q23564829 wd:Q19283882 wd:Q117235549 wd:Q117235579 wd:Q56915515 wd:Q61913008 wd:Q61053345 wd:Q117235557
p:P1476
wds:Q30315977-2164A397-04D9-4E25-AED1-8971F681BD37
wdt:P1476
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
p:P304
wds:Q30315977-AC460484-BE39-4953-A904-F2F49A51FB31
wdt:P304
1691-1699
p:P31
wds:Q30315977-A6A25105-C611-4415-A327-6302031A562A
wdt:P31
wd:Q13442814
p:P921
wds:Q30315977-18304C57-9CFF-495A-B5C8-2A4F7F7DB6F2 wds:Q30315977-3CF70C3D-0FFB-4E54-BD2D-500F78DC9F78 wds:Q30315977-FE67F857-E30A-4FF6-8E3F-032BCB90921C wds:Q30315977-EADD8028-30BC-4536-ACED-85402040E1F7
wdt:P921
wd:Q269829 wd:Q6934595 wd:Q29496 wd:Q42824440
p:P698
wds:Q30315977-66F7E4FD-FF19-438A-B1E1-F053EE0C3224
wdtn:P698
n11:26549589
wdt:P698
26549589
p:P1433
wds:Q30315977-54C8221F-E02B-4A3E-8627-75D988FEC326
wdt:P1433
wd:Q13747613
p:P433
wds:Q30315977-26446A79-B2A4-4F0D-A86D-9BF6BF95CC40
p:P478
wds:Q30315977-2949E88B-9A17-4167-9E9F-F1EA26406FA1
wdt:P433
16
wdt:P478
16
p:P1104
wds:Q30315977-5CD6E903-2D4E-478B-8DB7-4C45DDB6A5CF
wdt:P1104
9
p:P356
wds:Q30315977-89ABBF1B-A8EA-4CAE-9635-B7E5B629D7B8
wdtn:P356
n8:S1470-2045(15)00362-9
wdt:P356
10.1016/S1470-2045(15)00362-9